MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    The effects of bright light therapy on depression, sleep and circadian rhythm in patients with Parkinson’s disease and a depressive disorder: Results of a double-blind randomized controlled trial

    S. Rutten, C. Vriend, J. Smit, H. Berendse, E. van Someren, A. Hoogendoorn, J. Twisk, Y. vd Werf, O. vd Heuvel (Amsterdam, Netherlands)

    Objective: The aim of this study was to assess the efficacy of Bright Light Therapy (BLT) in reducing depressive symptoms in patients with Parkinson’s disease…
  • 2018 International Congress

    GASTROPARK: Multicenter study on the efficacy of dopamine agonists for gastrointestinal symptoms in Parkinson’s disease

    J. Martinez Castrillo, A. Alonso Canovas, G. Fernandez Pajarin, L. Vela Desojo, J. Garcia Caldentey, P. Sanchez Alonso, M. Fernandez Moreno, M. Mata, J. Herreros Rodriguez, J. Infante, J. Ruiz Martinez, C. Ruiz Huete, S. Fanjul Arbos, P. Garcia Ruiz (Madrid, Spain)

    Objective: Main: To assess the modification of gastrointestinal symptoms in patients with Parkinson's disease before and after the introduction of dopamine agonists. Secondary: (1) To…
  • 2018 International Congress

    Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: The BIPARK-I double-blind experience

    J. Kulisevsky, E. Tolosa, J. Ferreira, A. Lees, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

    Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a novel once-daily COMT inhibitor,…
  • 2018 International Congress

    Can choice of games influence the therapeutic results obtained by training in virtual reality for gait improvement in people with Parkinson’s disease?

    P. Barbosa, A. da Costa, A. Falconi, M. d'Alencar, M E. Piemonte (São Paulo, Brazil)

    Objective: The aim of this study was to compare the efficiency of two different combination of games to improve the gait performance in PPD. Background:…
  • 2018 International Congress

    Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the Phase 3 double-blind, placebo-controlled trial

    S. Factor, S. Isaacson, K. Sciarappa, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Atlanta, GA, USA)

    Objective: To evaluate the efficacy of APL-130277 (APL) in a double-blind, placebo-controlled trial. Background: OFF episodes are a common, disabling complication of Parkinson’s disease (PD)…
  • 2018 International Congress

    Effect of mindfulness yoga on psychological distress in people with Parkinson’s disease (PD): A randomized controlled trial

    J.Y.Y. Kwok, J.C.Y. Kwan, M. Auyeung, C.T. Mok, C.K.Y. Lau, H.Y.L. Chan (New Territories, Hong Kong)

    Objective: To determine the effects of yoga versus conventional stretching and resistance training exercises (SRTE) on psychological, physical, spiritual, and health-related quality-of-life (HRQOL) outcomes among…
  • 2018 International Congress

    Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture

    J. Ferrario, A. Bernardi, P. Ballestero, M. Ferrario, M. Schenk, E. Avale, S. Guerrero, O. Gershanik (Buenos Aires, Argentina)

    Objective: To evaluate the effect of Mate leaves extracts on the survival and maturation of dopaminergic neurons in vitro. Background: Parkinson's disease (PD) is caused…
  • 2018 International Congress

    Long-Duration Response to Levodopa in advanced Parkinson’s Disease: Relevance for RCT on Disease-Modifying therapies

    R. Cilia, E. Cereda, A. Akpalu, S. Sarfo, M. Cham, G. Pezzoli (Milan, Italy)

    Objective: (1) To investigate the natural history of Parkinson’s disease (PD) in a cohort of newly diagnosed patients and (2) the response to acute levodopa…
  • 2018 International Congress

    The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease

    C. Kwan, I. Frouni, D. Bedard, A. Hamadjida, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…
  • 2018 International Congress

    Exploring the utility of the ChulaPD intelligent Parkinson’s disease car to determine naturalistic driving ability in Parkinson’s disease patients: A pilot study of 10 patients

    O. Jitkritsadakul, S. Krootjohn, P. Yanthitirat, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To examine the naturalistic driving performance in PD patients compared to controls and to determine if the PD patients showed diminished abilities. Background: Competence…
  • « Previous Page
  • 1
  • …
  • 1425
  • 1426
  • 1427
  • 1428
  • 1429
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley